About the Committee
BioNJ’s Public Policy Committee ensures that BioNJ has a position on relevant legislative and regulatory proposals and programs. The Committee is comprised of BioNJ Innovation Members who serve for a one-year term at the invitation of the Committee Chairman or Co-Chairmen and the President and CEO of BioNJ. The Committee meets on a quarterly or as-needed basis.
Ambaw Bellete, Photocure, Inc., Committee Co-Chairman
James Sapirstein, R. Ph., MBA, ContraVir Pharmaceuticals, Inc., Committee Co-Chairman
Paul G. Howes, ThromboGenics, Inc.
Sarah Kan, Novartis Pharmaceuticals
Brian Kelly, Novo Nordisk
Wendy Lazarus, Pfizer
John Maki, Vicus Pharmaceuticals
Scott Megaffin, Churchill Pharmaceuticals
Daniel O’Connor, Advaxis, Inc.
Dmitri Siegel, Celgene Corporation
Debbie Hart, BioNJ
Rebecca Perkins, BioNJ
Sonia Delgado, PPAG